| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 825 | 2018 |
| HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018 | 699 | 2018 |
| Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers K Jhaveri, T Taldone, S Modi, G Chiosis Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1823 (3), 742-755, 2012 | 517 | 2012 |
| Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors N Vasan, P Razavi, JL Johnson, H Shao, H Shah, A Antoine, E Ladewig, ... Science 366 (6466), 714-723, 2019 | 237 | 2019 |
| Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update F Andre, N Ismaila, KH Allison, WE Barlow, DE Collyar, S Damodaran, ... Journal of Clinical Oncology 40 (16), 1816-1837, 2022 | 210 | 2022 |
| Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions K Jhaveri, SO Ochiana, MPS Dunphy, JF Gerecitano, AD Corben, RI Peter, ... Expert opinion on investigational drugs 23 (5), 611-628, 2014 | 191 | 2014 |
| Capivasertib in hormone receptor–positive advanced breast cancer NC Turner, M Oliveira, SJ Howell, F Dalenc, J Cortes, HL Gomez Moreno, ... New England Journal of Medicine 388 (22), 2058-2070, 2023 | 166 | 2023 |
| Sacituzumab govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer HS Rugo, A Bardia, F Marmé, J Cortes, P Schmid, D Loirat, O Trédan, ... Journal of Clinical Oncology 40 (29), 3365-3376, 2022 | 161 | 2022 |
| ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer G Xu, S Chhangawala, E Cocco, P Razavi, Y Cai, JE Otto, L Ferrando, ... Nature genetics 52 (2), 198-207, 2020 | 159 | 2020 |
| HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development JC Singh, K Jhaveri, FJ Esteva British journal of cancer 111 (10), 1888-1898, 2014 | 139 | 2014 |
| First-in-human human epidermal growth factor receptor 2–targeted imaging using 89Zr-Pertuzumab PET/CT: dosimetry and clinical application in patients with breast cancer GA Ulaner, SK Lyashchenko, C Riedl, S Ruan, PB Zanzonico, D Lake, ... Journal of Nuclear Medicine 59 (6), 900-906, 2018 | 137 | 2018 |
| Current status of hybrid PET/MRI in oncologic imaging AB Rosenkrantz, K Friedman, H Chandarana, A Melsaether, L Moy, ... American journal of roentgenology 206 (1), 162-172, 2016 | 124 | 2016 |
| Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI … KL Jhaveri, XV Wang, V Makker, SW Luoh, EP Mitchell, JA Zwiebel, ... Annals of Oncology 30 (11), 1821-1830, 2019 | 120 | 2019 |
| Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors P Razavi, MN Dickler, PD Shah, W Toy, DN Brown, HH Won, BT Li, ... Nature Cancer 1 (4), 382-393, 2020 | 119 | 2020 |
| Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor … HS Rugo, A Bardia, F Marmé, J Cortes, P Schmid, D Loirat, O Tredan, ... Journal of Clinical Oncology 40 (17_suppl), LBA1001-LBA1001, 2022 | 114 | 2022 |
| Comparison of Whole-Body 18F FDG PET/MR Imaging and Whole-Body 18F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with … AN Melsaether, RA Raad, AC Pujara, FD Ponzo, KM Pysarenko, ... Radiology 281 (1), 193-202, 2016 | 112 | 2016 |
| Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer LM Smyth, SA Piha-Paul, HH Won, AM Schram, C Saura, S Loi, J Lu, ... Cancer discovery 10 (2), 198-213, 2020 | 111 | 2020 |
| A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer K Jhaveri, S Chandarlapaty, D Lake, T Gilewski, M Robson, S Goldfarb, ... Clinical breast cancer 14 (3), 154-160, 2014 | 110 | 2014 |
| Head-to-head evaluation of 18F-FES and 18F-FDG PET/CT in metastatic invasive lobular breast cancer GA Ulaner, K Jhaveri, S Chandarlapaty, V Hatzoglou, CC Riedl, JS Lewis, ... Journal of Nuclear Medicine 62 (3), 326-331, 2021 | 106 | 2021 |
| Ganetespib: research and clinical development K Jhaveri, S Modi OncoTargets and therapy, 1849-1858, 2015 | 106 | 2015 |
